25 Mar 2024 Tai Hing’s FY23 revenue incr
CROSBY Research – Tai Hing (6811 HK): Turnaround in FY23 with a generous payout ratio
CROSBY Research – Vincent Medical (1612 HK/BUY): Achieving financial turnaround in FY23
21 Mar 2024 Vincent Medical’s FY23 turno
CROSBY Research – Xiaomi Corporation (1810 HK): Solid 4Q23 core business recovery; launching of new EV will be near-term catalyst
21 Mar 2024 Xiaomi reported 4Q23 results
CROSBY Research – Xtep International (1368 HK/BUY): Inline FY23 results ; Saucony achieved profitability
19 Mar 2024 Xtep’s FY23 revenue was up b
CROSBY Research – China Lilang (1234 HK): Expects at least 15% retail sales growth in FY24
19 Mar 2024 The company reported a 14.8%
CROSBY Research – Wasion Holdings (3393 HK/BUY): Strong FY23 NP growth on solid revenue growth and GPM improvement
18 Mar 2024 Following the positive profi
CROSBY Research – Giordano (709 HK): FY23 NP rose by 29% YoY on higher GPM and operating leverage
18 Mar 2024 FY23 revenue slightly increa
CROSBY Research – 361 Degrees (1361 HK/BUY): Solid FY23 results with strong growth from Kids and online segments
14 Mar 2024 FY23 revenue was up 21.0% Yo
CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 54)
11 Mar 2024 (Bloomberg) Hong Kong’s 10 b
CROSBY Research – Concord (182 HK/BUY): Solid FY23 results
08 Mar 2024 CNE’s FY23 revenue was up by